{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036936","form_type":"8-K/A","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-08-11T00:16:16+00:00","discovered_at":"2026-08-11T10:10:00.346714+00:00","generated_at":"2026-08-11T10:11:00.086708+00:00","sec_items":["7.01","2.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Elite Pharmaceuticals schedules Aug 13 release of Q1 FY2027 results, Aug 14 call","bullets":["Q1 FY2027 (ended June 30, 2026) financial results to be released Thursday, August 13, 2026.","Conference call Friday, August 14, 2026 at 11:30 AM EDT; dial-in 1-800-346-7359 (US), 1-973-528-0008 (intl), conference number 98840.","8-K/A amends prior notice, correcting event dates from November to August 2026.","Stockholder questions accepted via dianne@elitepharma.com; general Qs by Aug 12, financial Qs by Aug 13, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036936","json":"https://secwatch.observer/filing/0001493152-26-036936.json","markdown":"https://secwatch.observer/filing/0001493152-26-036936.md","text":"https://secwatch.observer/filing/0001493152-26-036936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226036936/0001493152-26-036936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226036936/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T10:11:00.086708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}